2023
DOI: 10.3390/jcm12247529
|View full text |Cite
|
Sign up to set email alerts
|

Intensive Care Unit-Acquired Weakness after Liver Transplantation: Analysis of Seven Cases and a Literature Review

Rita Gaspari,
Giorgia Spinazzola,
Paola Aceto
et al.

Abstract: Intensive Care Unit (ICU)-Acquired Weakness (ICU-AW) is a generalized muscle weakness that is clinically detected in critical patients and has no plausible etiology other than critical illness. ICU-AW is uncommon in patients undergoing orthotopic liver transplantation (OLT). Our report sheds light on the highest number of ICU-AW cases observed in a single center on OLT patients with early allograft dysfunction. Out of 282 patients who underwent OLT from January 2015 to June 2023, 7 (2.5%) developed generalized… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 53 publications
1
0
0
Order By: Relevance
“…We also observed a significant decrease in the platelet count, as reported by other authors, in patients who underwent hemoadsorption for "hepatic indications" [9,10,18]. In our patients, the decrease in platelet count was clinically substantial and required multiple transfusions, with a potential negative impact exerted on clinical outcomes, including an increased occurrence of severe complications and higher mortality [21][22][23][24][25][26][27]. Thrombocytopenia was also the most frequent adverse event in a large cohort of patients treated with MARS ® therapy [28].…”
Section: Discussionsupporting
confidence: 78%
“…We also observed a significant decrease in the platelet count, as reported by other authors, in patients who underwent hemoadsorption for "hepatic indications" [9,10,18]. In our patients, the decrease in platelet count was clinically substantial and required multiple transfusions, with a potential negative impact exerted on clinical outcomes, including an increased occurrence of severe complications and higher mortality [21][22][23][24][25][26][27]. Thrombocytopenia was also the most frequent adverse event in a large cohort of patients treated with MARS ® therapy [28].…”
Section: Discussionsupporting
confidence: 78%